Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis

被引：18

作者：

Solerte, SB

Fioravanti, M

Racchi, M

Trabucchi, M

Zanetti, O

Govoni, S

机构：

[1] Univ Pavia, Inst Pharmacol, I-27100 Pavia, Italy

[2] Univ Pavia, Dept Internal Med, Geriatr & Gerontol Clin, I-27100 Pavia, Italy

[3] IRCCS San Giovanni Dio, Osped Sacro Cuore Gesu Fatebenefratelli, Brescia, Italy

[4] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy

来源：

MATURITAS | 1999年 / 31卷 / 02期

关键词：

Alzheimer's disease; estrogens; neuroprotection; apolipoprotein E; risk factors; amyloid precursor; protein; neuroimmune interactions; glucose metabolism;

D O I：

10.1016/S0378-5122(98)00111-X

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The positive efficacy of estrogen replacement therapy (ERT) in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) is a matter of intense debate among clinicians and neuroscientists. The experimental and preliminary clinical evidence supporting the use of ERT are based on epidemiological data and on the study of the effect of estrogens on several aspects of brain homeostasis, including the modulation of neurotransmitters and vascular changes. In spite of numerous data available the mechanisms underlying the putative estrogen effects in neurodegenerative diseases are largely unknown. The aim of this paper is to discuss and elaborate on some of the hypotheses and controversial findings currently present in this field (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：95 / 101

页数：7

共 68 条

[1] Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus [J].